Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2025)

Historic Gross Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 85.22%.

  • Xeris Biopharma Holdings' Gross Margin rose 102600.0% to 85.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.56%, marking a year-over-year increase of 32000.0%. This contributed to the annual value of 81.86% for FY2024, which is 6600.0% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Gross Margin stood at 85.22% for Q3 2025, which was up 102600.0% from 83.37% recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Gross Margin high stood at 85.48% for Q1 2025, and its period low was 62.01% during Q2 2021.
  • Moreover, its 5-year median value for Gross Margin was 82.3% (2022), whereas its average is 79.8%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 236300bps in 2021, then plummeted by -80800bps in 2024.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Gross Margin stood at 77.19% in 2021, then grew by 5bps to 81.02% in 2022, then grew by 2bps to 82.95% in 2023, then rose by 2bps to 84.23% in 2024, then rose by 1bps to 85.22% in 2025.
  • Its last three reported values are 85.22% in Q3 2025, 83.37% for Q2 2025, and 85.48% during Q1 2025.